Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CStone Pharma Approved to Begin US Trial of PD-1 Candidate

publication date: Oct 24, 2018

CStone Pharma of Suzhou received permission from US clinical trials of its novel PD-1 mAb, CS1003. One week ago, CStone announced a US approval to start a trial of another immunoncology candidate, its PD-L1 molecule, CS1001. Both candidates are full-length, humanized immunoglobulin G4 (IgG4) mAbs, and both showed good tolerability and efficacy in preclinical studies. In May, CStone began a Phase I trial of the PD-1 candidate in Australia. The Phase I trials will determine the Phase II dose for CS1003 in solid tumor patients. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here